Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
In this article we talk about 15 fastest growing biotech companies in the US. You can skip our detailed analysis of the biotech industry and go to 5 Fastest Growing Biotech Companies in the US. Biotechnology is one of the most consequential domains of the healthcare industry. Biotechnology uses biology and the functions of living […]
There's been a notable change in appetite for Fate Therapeutics, Inc. ( NASDAQ:FATE ) shares in the week since its...
FATE reports a wider Q4 loss on increased R&D expenses.
FATE earnings call for the period ending December 31, 2020.
Shares of Fate Therapeutics (NASDAQ:FATE) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 64.86% over the past year to ($0.61), which missed the estimate of ($0.39). Revenue of $15,896,000 higher by 467.31% from the same period last year, which beat the estimate of $4,870,000. Looking Ahead Earnings guidance hasn't been issued by the company for now. Revenue guidance hasn't been issued by the company for now. Details Of The Call ...
Positive Interim Data Reported from FT516 Phase 1 Study in Relapsed / Refractory BCL; Objective Responses, including Two Complete Responses, Achieved in 3 of 4 Patients in Dose Cohorts 2 and 3 Clinical Activity of FT596 as Monotherapy Demonstrated in Refractory DLBCL; Partial Response Achieved, with Deepening of Response upon FT596 Retreatment, in Patient in Dose Cohort 1 IND Application Allowed by FDA for FT576, the First-ever Cell Therapy Engineered with Four Functional Anti-Tumor Modalities; ...
NEW YORK, NY / ACCESSWIRE / February 24, 2021 / Fate Therapeutics, Inc. (NASDAQ:FATE) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 24, 2021 at 5:00 PM Eastern Time.